A Phase 3 interventional study of OPC-34712 and OPC-34712 in Acute Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 60 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-11-26.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.
Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 2nd largest by enrollment, is one of 7 that started in 2011, is one of 16 in phase 3, and was the 5th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:
New York State Psychiatric Institute
Ages 18–55
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 17 · Phase 4 1
First in 2008; this study’s year is marked. 7 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 674 is above the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 155 across the 28 interventional studies. Of the 26 that completed or were terminated, 22 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 28 have an industry lead sponsor. The 7 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 9th largest by enrollment of the 111 interventional ones that give a count, is one of 9 that started in 2011, is one of 50 in phase 3, and was the 38th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing brexpiprazole in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety, and tolerability of fixed doses of OPC-34712 versus placebo for the treatment of adult subjects with an acute relapse of schizophrenia.
Schizophrenia is a severely debilitating mental illness that affects approximately 1% of the world population. Hallucinations and delusions are the most striking characteristic positive symptoms of schizophrenia; however, more subtle negative symptoms (eg, social withdrawal and lack of emotion, energy, and motivation) may also be present. The first antipsychotics developed for the treatment of schizophrenia were effective against positive symptoms, but showed little efficacy for negative symptoms and were also associated with a high incidence of side effects. Second generation antipsychotics, represent a significant advancement in the treatment of psychotic disorders because they are effective and at the same time exhibit fewer side effects than first generation antipsychotics. Although generally safer than first generation antipsychotics, the second-generation antipsychotics are not devoid of undesirable side effects such as Hyperprolactinemia and weight gain. In addition, the safety of these drugs vary considerably.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a current Axis I diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Higher dose, tablet, once daily, for six weeks
Drug: OPC-34712
Middle dose, tablet, once daily, for six weeks
Drug: OPC-34712
Lower dose, tablet, once daily, for six weeks
Drug: OPC-34712
Placebo, once daily, for six weeks
Drug: Placebo
Higher dose tablet, once daily, for six weeks,
Middle dose tablet, once daily, for six weeks
Lower dose tablet, once daily, for six weeks
Placebo, once daily, for six weeks
Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score.
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S) Score.
Severity of illness for each participant was rated using the CGI-S, which was the key secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in Personal and Social Performance (PSP) Score.
PSP is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
Time frame: Baseline, Week 3 and Week 6
Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome). The analysis of secondary endpoints was conducted if both comparisons of brexpiprazole 4 mg/day vs placebo and brexpiprazole 2 mg/day vs placebo of the primary endpoint were significant. Although only the comparison of brexpiprazole 4 mg/day vs placebo met the gatekeeping threshold in the primary analysis, statistical testing for the other doses was reported for information.
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
Time frame: Week 6
Percentage of Participants With Response at Week 6.
The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of 1 or 2.
Time frame: Week 6
Percentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6.
Participants discontinued for lack of efficacy during the trial were reported here.
Time frame: Week 6
Mean Change From Baseline to Week 6 in PANSS Excited Component (PEC) Score.
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Positive Symptoms Score.
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Negative Symptoms Score.
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Disorganized Thought Score.
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Uncontrolled Hostility and Excitement Score.
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
Mean Change From Baseline to Week 6 in PANSS Marder Factor Scores: Anxiety and Depression Score.
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
Time frame: Baseline, Weeks 1, 2, 3, 4, 5, and 6
This trial was conducted in 674 participants from 68 trial sites in 8 countries.
| Milestone | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Started | 120 | 186 | 184 | 184 |
| Completed | 81 | 129 | 130 | 118 |
| Not completed | 39 | 57 | 54 | 66 |
| Withdrew: Adverse event | 11 | 11 | 13 | 22 |
| Withdrew: Participant met withdrawal criteria | 0 | 0 | 2 | 1 |
| Withdrew: Physician decision | 2 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 15 | 25 | 23 | 21 |
| Withdrew: Protocol deviation | 2 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 9 | 20 | 16 | 21 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -3.32 ± 0.83 | -4.35 ± 0.68 | -5.58 ± 0.68 | -3.48 ± 0.68 |
| Week 2 | -7.61 ± 1.09 | -8.70 ± 0.88 | -8.42 ± 0.88 | -6.61 ± 0.89 |
| Week 3 | -11.56 ± 1.30 | -10.69 ± 1.06 | -12.63 ± 1.05 | -8.95 ± 1.06 |
| Week 4 | -13.97 ± 1.49 | -13.12 ± 1.21 | -15.55 ± 1.19 | -11.10 ± 1.22 |
| Week 5 | -14.47 ± 1.71 | -14.11 ± 1.38 | -17.26 ± 1.37 | -11.89 ± 1.40 |
| Week 6 | -16.90 ± 1.86 | -16.61 ± 1.49 | -20.00 ± 1.48 | -13.53 ± 1.52 |
Severity of illness for each participant was rated using the CGI-S, which was the key secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.11 ± 0.05 | -0.16 ± 0.04 | -0.22 ± 0.04 | -0.12 ± 0.04 |
| Week 2 | -0.31 ± 0.06 | -0.40 ± 0.05 | -0.40 ± 0.05 | -0.36 ± 0.05 |
| Week 3 | -0.63 ± 0.07 | -0.60 ± 0.06 | -0.69 ± 0.06 | -0.44 ± 0.06 |
| Week 4 | -0.67 ± 0.09 | -0.72 ± 0.07 | -0.85 ± 0.07 | -0.58 ± 0.07 |
| Week 5 | -0.81 ± 0.10 | -0.79 ± 0.08 | -1.02 ± 0.08 | -0.68 ± 0.08 |
| Week 6 | -0.91 ± 0.11 | -0.99 ± 0.09 | -1.19 ± 0.08 | -0.81 ± 0.09 |
PSP is a validated clinician-rated scale that measures personal and social functioning in 4 domains: socially useful activities (e.g. work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the rater's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 3 | 6.97 ± 0.90 | 6.85 ± 0.73 | 7.12 ± 0.71 | 5.80 ± 0.73 |
| Week 6 | 11.73 ± 1.19 | 10.52 ± 0.95 | 13.11 ± 0.94 | 8.52 ± 0.97 |
PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome). The analysis of secondary endpoints was conducted if both comparisons of brexpiprazole 4 mg/day vs placebo and brexpiprazole 2 mg/day vs placebo of the primary endpoint were significant. Although only the comparison of brexpiprazole 4 mg/day vs placebo met the gatekeeping threshold in the primary analysis, statistical testing for the other doses was reported for information.
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.93 ± 0.28 | -1.43 ± 0.23 | -1.80 ± 0.23 | -1.25 ± 0.23 |
| Week 2 | -2.54 ± 0.39 | -2.76 ± 0.32 | -2.93 ± 0.32 | -2.56 ± 0.32 |
| Week 3 | -3.94 ± 0.46 | -3.56 ± 0.37 | -4.43 ± 0.37 | -3.34 ± 0.37 |
| Week 4 | -4.83 ± 0.52 | -4.35 ± 0.42 | -5.16 ± 0.41 | -3.93 ± 0.42 |
| Week 5 | -4.80 ± 0.58 | -4.68 ± 0.47 | -6.04 ± 0.46 | -4.33 ± 0.47 |
| Week 6 | -5.63 ± 0.62 | -5.42 ± 0.50 | -6.65 ± 0.50 | -4.95 ± 0.51 |
The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.31 ± 0.25 | -0.52 ± 0.20 | -0.88 ± 0.20 | -0.40 ± 0.20 |
| Week 2 | -1.27 ± 0.29 | -1.31 ± 0.23 | -1.42 ± 0.23 | -0.79 ± 0.24 |
| Week 3 | -2.06 ± 0.35 | -1.80 ± 0.28 | -2.15 ± 0.28 | -1.18 ± 0.28 |
| Week 4 | -2.56 ± 0.40 | -2.09 ± 0.32 | -2.69 ± 0.32 | -1.67 ± 0.33 |
| Week 5 | -2.71 ± 0.44 | -2.50 ± 0.35 | -2.82 ± 0.35 | -1.74 ± 0.36 |
| Week 6 | -2.92 ± 0.48 | -2.91 ± 0.38 | -3.36 ± 0.38 | -2.14 ± 0.39 |
The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6. | 3.20 ± 1.45 | 3.17 ± 1.34 | 2.95 ± 1.33 | 3.48 ± 1.46 |
The response rate was defined as reduction of ≥30% from Baseline in PANSS Total Score or CGI-I score of 1 or 2.
| percentage of participants | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Response at Week 6. | 43.6 | 38.5 | 49.7 | 31.7 |
Participants discontinued for lack of efficacy during the trial were reported here.
| percentage of participants | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants With Discontinuation Rate for Lack of Efficacy at Week 6. | 7.69 | 11.2 | 8.84 | 11.7 |
The PEC score consisted of five PANSS items: excitement (P4), hostility (P7), tension (G4), uncooperativeness (G8), and poor impulse control (G14). Each of the items were rated on a scale of 1 (absent) to 7 (extreme). The PEC scores ranged from 5 (not present) to 35 (extremely severe).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.35 ± 0.25 | -0.46 ± 0.21 | -1.01 ± 0.21 | -0.48 ± 0.21 |
| Week 2 | -0.76 ± 0.32 | -1.31 ± 0.26 | -1.21 ± 0.26 | -0.62 ± 0.26 |
| Week 3 | -1.21 ± 0.35 | -1.31 ± 0.28 | -1.81 ± 0.28 | -0.82 ± 0.29 |
| Week 4 | -1.58 ± 0.37 | -1.52 ± 0.29 | -2.12 ± 0.29 | -1.12 ± 0.30 |
| Week 5 | -1.16 ± 0.42 | -1.48 ± 0.34 | -2.27 ± 0.34 | -0.97 ± 0.35 |
| Week 6 | -1.94 ± 0.41 | -1.90 ± 0.33 | -2.86 ± 0.33 | -1.47 ± 0.34 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The positive factor score is the sum of the 8 components of the positive symptoms scale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -1.44 ± 0.29 | -1.77 ± 0.23 | -1.75 ± 0.24 | -1.30 ± 0.24 |
| Week 2 | -2.97 ± 0.39 | -3.10 ± 0.32 | -3.03 ± 0.32 | -3.03 ± 0.32 |
| Week 3 | -4.48 ± 0.47 | -4.09 ± 0.38 | -4.39 ± 0.37 | -3.78 ± 0.38 |
| Week 4 | -5.42 ± 0.53 | -4.93 ± 0.43 | -5.48 ± 0.43 | -4.67 ± 0.44 |
| Week 5 | -5.86 ± 0.58 | -5.35 ± 0.47 | -6.41 ± 0.46 | -5.47 ± 0.47 |
| Week 6 | -6.56 ± 0.66 | -6.26 ± 0.53 | -7.05 ± 0.53 | -5.91 ± 0.54 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The negative factor score is the sum of the 7 items of the negative subscale (range: 8 - best possible outcome to 56 - worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.70 ± 0.28 | -0.85 ± 0.22 | -1.12 ± 0.23 | -0.66 ± 0.22 |
| Week 2 | -1.71 ± 0.32 | -1.86 ± 0.26 | -1.72 ± 0.26 | -1.38 ± 0.26 |
| Week 3 | -2.55 ± 0.37 | -2.30 ± 0.30 | -2.64 ± 0.30 | -1.83 ± 0.30 |
| Week 4 | -3.21 ± 0.43 | -2.63 ± 0.34 | -3.17 ± 0.34 | -2.16 ± 0.35 |
| Week 5 | -3.35 ± 0.47 | -3.13 ± 0.38 | -3.21 ± 0.37 | -2.24 ± 0.38 |
| Week 6 | -3.55 ± 0.48 | -3.53 ± 0.39 | -3.84 ± 0.39 | -2.55 ± 0.40 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The disorganized thoughts factor score is the sum of score from the 7 items on the disorganized thoughts subscale (range: 7 - best possible outcome to 49 - worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -0.40 ± 0.23 | -0.46 ± 0.19 | -0.78 ± 0.19 | -0.42 ± 0.19 |
| Week 2 | -1.42 ± 0.27 | -1.15 ± 0.22 | -1.37 ± 0.22 | -0.71 ± 0.23 |
| Week 3 | -2.35 ± 0.31 | -1.71 ± 0.25 | -2.32 ± 0.25 | -1.35 ± 0.26 |
| Week 4 | -2.56 ± 0.36 | -2.27 ± 0.29 | -2.83 ± 0.29 | -1.77 ± 0.30 |
| Week 5 | -2.95 ± 0.41 | -2.55 ± 0.33 | -3.42 ± 0.32 | -2.01 ± 0.33 |
| Week 6 | -3.46 ± 0.43 | -2.94 ± 0.35 | -3.98 ± 0.34 | -2.59 ± 0.35 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The uncontrolled hostility/excitement factor score is the sum of score from the 4 items on the uncontrolled hostility/excitement subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | 0.03 ± 0.22 | -0.10 ± 0.18 | -0.63 ± 0.18 | -0.21 ± 0.18 |
| Week 2 | -0.15 ± 0.28 | -0.65 ± 0.23 | -0.68 ± 0.23 | -0.13 ± 0.23 |
| Week 3 | -0.46 ± 0.30 | -0.61 ± 0.24 | -1.16 ± 0.24 | -0.19 ± 0.24 |
| Week 4 | -0.74 ± 0.32 | -0.74 ± 0.26 | -1.31 ± 0.25 | -0.39 ± 0.26 |
| Week 5 | -0.34 ± 0.36 | -0.60 ± 0.29 | -1.50 ± 0.29 | -0.22 ± 0.30 |
| Week 6 | -0.90 ± 0.36 | -0.81 ± 0.29 | -1.89 ± 0.29 | -0.64 ± 0.30 |
Retrospective factor analyses have been performed in recent decades using scores for the 30 individual PANSS items to categorize symptoms into 5 dimensions. Collectively, these dimensions are referred to as the PANSS Marder Factor scores and include positive symptoms score, negative symptoms score, thought score, uncontrolled hostility/excitement, anxiety depression score. The anxiety/depression factor score is the sum of score from the 4 items on the anxiety/depression subscale (range: 4 - best possible outcome to 28 - worst possible outcome).
| Units on a scale | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| Week 1 | -1.18 ± 0.22 | -1.10 ± 0.18 | -1.26 ± 0.18 | -0.96 ± 0.18 |
| Week 2 | -1.86 ± 0.27 | -1.91 ± 0.22 | -1.60 ± 0.22 | -1.47 ± 0.22 |
| Week 3 | -2.43 ± 0.28 | -2.10 ± 0.23 | -2.24 ± 0.23 | -1.97 ± 0.23 |
| Week 4 | -2.85 ± 0.29 | -2.70 ± 0.23 | -2.93 ± 0.23 | -2.60 ± 0.23 |
| Week 5 | -2.93 ± 0.31 | -2.87 ± 0.25 | -3.09 ± 0.25 | -2.69 ± 0.26 |
| Week 6 | -3.57 ± 0.30 | -3.62 ± 0.24 | -3.78 ± 0.24 | -2.93 ± 0.24 |
Collected over Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 (+2) days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brexpiprazole 1 mg | — | 3/120 (2.5%) | 37/120 (30.8%) |
| Brexpiprazole 2 mg | — | 4/186 (2.2%) | 65/186 (34.9%) |
| Brexpiprazole 4 mg | — | 4/184 (2.2%) | 66/184 (35.9%) |
| Placebo | — | 10/184 (5.4%) | 71/184 (38.6%) |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| SchizophreniaPsychiatric disorders | 1/120 | 2/186 | 3/184 | 8/184 |
| Psychotic disorderPsychiatric disorders | 1/120 | 2/186 | 1/184 | 1/184 |
| AggressionPsychiatric disorders | 1/120 | 0/186 | 0/184 | 0/184 |
| IrritabilityGeneral disorders | 0/120 | 0/186 | 0/184 | 1/184 |
| Acute psychosisPsychiatric disorders | 0/120 | 0/186 | 0/184 | 1/184 |
| Suicidal ideationPsychiatric disorders | 0/120 | 0/186 | 1/184 | 0/184 |
| Event | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo |
|---|---|---|---|---|
| InsomniaPsychiatric disorders | 15/120 | 25/186 | 28/184 | 27/184 |
| HeadacheNervous system disorders | 9/120 | 20/186 | 19/184 | 27/184 |
| AgitationPsychiatric disorders | 10/120 | 16/186 | 13/184 | 13/184 |
| AkathisiaNervous system disorders | 5/120 | 9/186 | 12/184 | 13/184 |
| DyspepsiaGastrointestinal disorders | 7/120 | 7/186 | 6/184 | 6/184 |
| SchizophreniaPsychiatric disorders | 4/120 | 6/186 | 7/184 | 10/184 |
| Age, Continuous(Years) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 39.1 ± 11.9 | 36.9 ± 10.9 | 38.6 ± 11.0 | 39.3 ± 10.8 | 38.4 ± 11.1 |
| Sex: Female, Male(Participants) | Brexpiprazole 1 mg | Brexpiprazole 2 mg | Brexpiprazole 4 mg | Placebo | Total |
|---|---|---|---|---|---|
| Female | 43 | 64 | 71 | 73 | 251 |
| Male | 77 | 122 | 113 | 111 | 423 |
The record gives a start of Jul 2011, a primary completion of Feb 2014 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 9 months after primary completion. A results delay was requested in Feb 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →